Roth Capital Maintains Buy On RedHill Following 2015 Outlook
In a research report released today, Roth Capital analyst Scott Henry reiterated a Buy rating on RedHill Biopharma (NASDAQ:RDHL) with a $27.50 price target, after the company announced its 2015 outlook with anticipated key milestones.
Henry observed, “The main takeaways, in our opinion, include 1) RHB-105 H. pylori trial data remains on track for 2Q15, 2) a new, undisclosed, potentially sizable indication is on track to start clinical work mid-2015 for RHB-102, 3) validation coming for RHB-106 from a soon to start SLXP trial, and 4) potential 1H15 partnerships for RHB-101 and Rizaport.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Scott Henry has a total average return of 12.8% and a 50.6% success rate. Henry has a 31.0% average return when recommending RDHL, and is ranked #293 out of 3429 analysts.